Keros Therapeutics (NASDAQ:KROS) Issues Earnings Results

Keros Therapeutics (NASDAQ:KROS) released its quarterly earnings results on Wednesday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.93, Zacks reports. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The company had revenue of $14.26 million during the quarter, compared to analysts’ expectations of $4.22 million. During the same period last year, the business posted ($1.41) earnings per share. The firm’s revenue was up 3585.6% compared to the same quarter last year.

Keros Therapeutics Trading Up 1.8%

Shares of KROS traded up $0.28 during midday trading on Thursday, reaching $15.93. The stock had a trading volume of 987,001 shares, compared to its average volume of 912,007. The firm has a 50 day simple moving average of $15.46 and a 200-day simple moving average of $14.60. Keros Therapeutics has a one year low of $9.12 and a one year high of $72.37. The firm has a market cap of $485.51 million, a PE ratio of 51.43, a P/E/G ratio of 2.00 and a beta of 1.12.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $95,659,436.00. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 20.60% of the company’s stock.

Institutional Trading of Keros Therapeutics

A number of institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC acquired a new position in shares of Keros Therapeutics in the 1st quarter valued at approximately $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Keros Therapeutics by 15.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock valued at $227,000 after acquiring an additional 2,982 shares during the period. Goldman Sachs Group Inc. increased its position in Keros Therapeutics by 38.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after acquiring an additional 205,022 shares during the period. Creative Planning boosted its stake in shares of Keros Therapeutics by 40.2% in the 2nd quarter. Creative Planning now owns 24,226 shares of the company’s stock valued at $323,000 after purchasing an additional 6,948 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Keros Therapeutics by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock valued at $692,000 after purchasing an additional 7,146 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on KROS shares. Weiss Ratings reissued a “sell (d)” rating on shares of Keros Therapeutics in a report on Wednesday, October 8th. HC Wainwright cut their price objective on Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Wedbush increased their price objective on Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday. Finally, Wells Fargo & Company started coverage on Keros Therapeutics in a report on Monday, October 20th. They issued an “overweight” rating and a $26.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $30.11.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.